GeneDx Paid $36 Million for an AI Growth Engine. It's Worth $5 Million Now.

GeneDx Holdings paid $36.5 million to buy a company it described as a dynamic, recurring, revenue-generating platform. Twelve months later, that company is worth $5.3 million. That's roughly 85 percent of the purchase price, written off on a single earnings call in May.

The stock reacted as though the market was being told something it already suspected. Shares dropped 49 percent in one day, wiping out more than $900 million from GeneDx's market capitalization. A securities class action followed, naturally. The lead plaintiff deadline - the date by which investors with the biggest losses can step forward and direct the litigation - is August 3.

That's the sequence. The interesting part is the machinery behind it.

The acquisition as disclosure event

The obvious story here is that GeneDx bought something that didn't work. That's true. But the more revealing layer is what happened between the press release and the impairment charge, because that gap is where the stock price lived for a full year.

On April 16, 2025, GeneDx announced it was acquiring Fabric Genomics, an AI-driven genomic interpretation company. The total deal was worth up to $51 million, with up to $33 million in cash paid upfront. The company said Fabric's "software transforms static data into a dynamic, recurring revenue-generating platform - driving growth through software margins and high-leverage interpretation services across geographies and clinical use cases." The deal closed in May 2025 for $36.5 million.

For the next twelve months, that language - recurring revenue, software margins, scalable - did valuation work. Investors who bought WGS between April 2025 and May 2026 are the defined class in the lawsuit, because during that window, the market was pricing in a future where Fabric was a growth engine. Whether any particular investor bought the story or just held through it doesn't matter to the complaint. What matters is that the company kept telling the market the acquisition was going to expand GeneDx's addressable market, and the stock price accepted that premise.

Then on May 4, 2026, GeneDx reported first-quarter results and the story ended. The company disclosed that Fabric was really only suited for international markets, not the domestic recurring-revenue machine management had described. It recorded a $31.2 million impairment loss. It lowered full-year revenue guidance from $540–555 million to $475–490 million - a cut of roughly $65 million, or about 12 percent. Adjusted gross margin dropped from 74 percent to 69 percent. The company also missed its revenue targets for both its core exome and genome testing lines, blaming a product mix shift that management apparently hadn't signaled earlier.

One day later, the stock was down $33.42 a share.

The lawsuit plumbing

The class action, captioned Basma v. GeneDx Holdings Corp. (Case No. 26-cv-00880 in the District of Connecticut), alleges that GeneDx and certain officers made materially false or misleading statements about Fabric's viability and, by extension, about the company's overall business and prospects during the class period.

The lead plaintiff deadline of August 3 is part of the standard federal securities class-action process. Under the Private Securities Litigation Reform Act of 1995, the court appoints as lead plaintiff the investor or group of investors who has the largest financial stake in the case and is also "typical" and "adequate" to represent the class. The lead plaintiff then chooses which law firm runs the litigation. Investors who don't step up are still part of the class and share in any recovery, but they have no say in how the case is handled.

Multiple plaintiff firms are soliciting investors with substantial losses to file for lead plaintiff status. Courts generally favor the investor with the largest financial interest. The competition among law firms to represent the lead plaintiff is also competition over fees, because counsel is paid a percentage of the recovery, approved by the court.

So yes, the cascade of press releases you've seen from Kessler Topaz, Robbins Geller, Levi & Korsinsky, Kahn Swick, Hagens Berman, and others is partly about investor recovery and partly about the fee pipeline. That's how this side of the market works.

What actually went wrong

Stepping back from the litigation mechanics, there are two failures here, and they're not exactly the same thing.

The first is the acquisition itself. GeneDx paid $36.5 million for a technology that turned out to have no viable domestic commercial path. Whether that's poor due diligence, overpaying for an AI story, or something else - the complaint says the company knew or should have known Fabric had significant viability problems and didn't disclose them - is the substantive question the lawsuit argues over.

The second is the broader earnings miss that accompanied the impairment. The average reimbursement rate per test fell short of expectations, and the product mix shifted heavily toward genome sequencing, whose reimbursement is roughly half that of exome sequencing. Management had told investors in February that reimbursement would be flat and that genome and exome revenue growth would be 33–35 percent for 2026. By May, growth guidance was "at least 20 percent" and the revenue outlook had been cut by $65 million.

The impairment gets the headline, but the core business - the testing itself - is also underperforming the story that was sold. That makes the complaint harder to dismiss as just a failed acquisition. A botched M&A deal alone might be a business judgment investors accept. A botched deal plus a growth narrative that was already fraying before anyone knew about the impairment - that's closer to the kind of pattern securities law is designed to catch.

Where the stock is now

WGS is trading at $65.11 as of today, down roughly 62 percent from its 52-week high of $170.87 and about 50 percent year-to-date. The stock has recovered considerably from its May lows - it closed at $34.51 the day after the crash, and at $65.11 it's roughly double that level, up about 10 percent over the past five trading days - but the trajectory is still dominated by the May crash.

The structural question the lawsuit leaves open isn't whether GeneDx is now worth less than it was a year ago. It's whether the gap between the press release language and the impairment charge was a case of enthusiasm outrunning reality, or whether management was aware the story didn't hold and let the market trade on it anyway. The complaint says the latter. GeneDx hasn't commented publicly.

The simplest model is this: in a market that pays a premium for AI narratives in biotech, the space between "we bought a recurring revenue platform" and "that asset is worth $5.3 million" is where the legal theory lives. Whether a court finds that gap was an honest mistake or a disclosure failure is the question the next few months will sort out.